Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.

10 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

Downstream cancer care linked to complications during surgery

Patients who have complications after colorectal cancer surgery are less likely to get chemotherapy, even when it is clearly recommended for their diagnosis, a new study from the University of Michigan Comprehensive Cancer Center finds.

9 Dec 2010

AltheaDx partners with Compendia Bioscience to launch Breast Cancer Segregation Panel Assay

AltheaDx, Inc. today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials.

9 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

Study shows testing between colonoscopies helps detect CRC, advanced tumors

Among patients with a family or past history of colorectal cancer, testing between colonoscopies helps detect CRC and advanced tumors that are either missed or develop rapidly, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

8 Dec 2010

Low-dose aspirin enhances fecal occult blood test performance for detecting colorectal cancer

Use of low-dose aspirin prior to a newer type of fecal occult blood test is associated with a higher sensitivity for detecting advanced colorectal tumors, compared to no aspirin use, according to a study in the December 8 issue of JAMA.

8 Dec 2010

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health, in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.

8 Dec 2010

Humble aspirin reduces cancer death rates

A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.

7 Dec 2010

$Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010$

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.

7 Dec 2010

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.

7 Dec 2010

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.

7 Dec 2010

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

2 Dec 2010

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced that the University of Southern California (USC) has purchased the WaferGen SmartChip system for its USC Center for Molecular Pathways and Drug Discovery to discover and validate biomarkers for pancreatic and colorectal cancer applications to expedite the development of a cancer therapy. USC purchased a solution that includes the SmartChip platform and validated gene panels for biomarker profiling.

1 Dec 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Myriad Genetics, Inc. today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome called Lynch Syndrome, is both medically and cost effective.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Expert discusses androgen deprivation therapy for prostate cancer

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Downstream cancer care linked to complications during surgery

AltheaDx partners with Compendia Bioscience to launch Breast Cancer Segregation Panel Assay

ChipDX validates genetic signature for early-stage colon cancer

Study shows testing between colonoscopies helps detect CRC, advanced tumors

Low-dose aspirin enhances fecal occult blood test performance for detecting colorectal cancer

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Humble aspirin reduces cancer death rates

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

Debiopharm recognised with European Biopharmaceuticals company of the year award

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in